Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Growth hormone releasing hormone (GHRH) combined with arginine is a diagnostic test used to evaluate growth hormone (GH) secretion and function. This combination works synergistically to stimulate the release of growth hormone from the pituitary gland. Arginine suppresses somatostatin (the endogenous inhibitory regulator of GH) and induces GHRH release, while GHRH directly stimulates the pituitary to secrete GH. The combined administration produces a significantly greater GH response than either component alone, making it valuable for diagnosing growth hormone deficiency and evaluating pituitary function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on growth hormone releasing hormone + arginine.